Skip to main content

Athersys, Inc. (ATHX)

NASDAQ: ATHX · Delayed Price · USD
1.41
-0.02 (-1.40%)
Pre-market:Sep 24, 2021 5:26 AM EDT
1.43
0.02 (1.42%)
At close: Sep 23, 4:00 PM
Market Cap319.02M
Revenue (ttm)1.36M
Net Income (ttm)-93.82M
Shares Out222.44M
EPS (ttm)-0.45
PE Ration/a
Forward PE1.81
Dividendn/a
Ex-Dividend Daten/a
Volume1,179,633
Open1.43
Previous Close1.41
Day's Range1.40 - 1.44
52-Week Range1.35 - 3.03
Beta-1.72
AnalystsStrong Buy
Price Target5.75 (+302.1%)
Est. Earnings DateNov 9, 2021

About ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ...

IndustryBiotechnology
Founded1995
CEOGil Van Bokkelen
Employees97
Stock ExchangeNASDAQ
Ticker SymbolATHX
Full Company Profile

Financial Performance

In 2020, Athersys's revenue was $1.44 million, a decrease of -74.44% compared to the previous year's $5.63 million. Losses were -$78.77 million, 76.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Athersys stock is "Strong Buy." The 12-month stock price forecast is 5.75, which is an increase of 302.10% from the latest price.

Price Target
$5.75
(302.10% upside)
Analyst Consensus: Strong Buy

News

Are Options Traders Betting on a Big Move in Athersys (ATHX) Stock?

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

1 day ago - Zacks Investment Research

Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.

1 month ago - Business Wire

Athersys: Q2 Earnings Insights

Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.10), which w...

1 month ago - Benzinga

Athersys Reports Second Quarter 2021 Results

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys reports Q2 earnings and positive topline ARDS data evaluating MultiStem® from its partner HEALIOS, K.K. The companies advance partnership.

1 month ago - Business Wire

Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome...

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Healios announces positive topline clinical data from the ONE-BRIDGE study evaluating MultiStem for acute respiratory distress syndrome (ARDS).

1 month ago - Business Wire

Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership

CLEVELAND & TOKYO--(BUSINESS WIRE)---- $ATHX #Athersys--Healios and Athersys deepen their partnership and improve the collaboration agreement to enhance preparations for commercial activity in Japan.

1 month ago - Business Wire

Athersys to Host Second Quarter Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX #athersys--Athersys to Host Second Quarter Financial Results Call on August 9th, 2021.

2 months ago - Business Wire

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response i...

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ATHX--Peer-reviewed publication provides evidence of MAPC / MultiStem mechanisms of action on the inflammatory response by promoting Treg differentiation.

2 months ago - Business Wire

Athersys Reports First Quarter 2021 Results

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys reports First Quarter 2021 financial results and will provide a corporate update today at 4:30 PM EDT.

4 months ago - Business Wire

Athersys to Present at the Bank of America Virtual Healthcare Conference on May 12

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Ivor Macleod, CFO of Athersys Inc. is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 12th.

4 months ago - Business Wire

Athersys, Inc. (ATHX) Upgraded to Buy: Here's What You Should Know

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research

Athersys to Host First Quarter Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX #earnings--Athersys, Inc. will host its first quarter 2021 financial results call on Thursday, May 6, 2021 at 4:30 PM EDT.

5 months ago - Business Wire

Athersys to Present at the Needham Virtual Healthcare Conference on April 14

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 14th and the event will be webcast.

5 months ago - Business Wire

Why Athersys Stock Jumped Today

The biotech's partner completed enrollment in a key clinical study.

5 months ago - The Motley Fool

Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Di...

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys partner in Japan, HEALIOS KK, completes enrollment in the ONE-BRIDGE study evaluating MulitiStem cell therapy for the treatment of ARDS.

5 months ago - Business Wire

Athersys Announces Financial Results for Fourth Quarter and Full Year 2020

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys continues to develop large-scale manufacturing processes and advance MultiStem cell therapy clinical trials for stroke, ARDS, and trauma.

5 months ago - Business Wire

Athersys to Host Year-End 2020 Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.

6 months ago - Business Wire

Athersys Announces Cooperation Agreement With HEALIOS K.K.

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.

7 months ago - Business Wire

Athersys Announces CEO Transition

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys

7 months ago - Business Wire

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

7 months ago - Seeking Alpha

Athersys to Host a Virtual Investor Day

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.

7 months ago - Business Wire

Athersys (ATHX) Surges: Stock Moves 8.8% Higher

Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem®...

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries

9 months ago - Business Wire

Athersys Announces Three Appointments to Board of Directors

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.

10 months ago - Business Wire